pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 23·1 min read
save

Advocacy group Public Citizen petitions FDA to ban direct-to-consumer prescription drug ads

Jul 23, 2026·read at STAT ↗RegulatoryNegative

Public Citizen has filed a petition with the U.S. Food and Drug Administration calling for a ban on direct-to-consumer advertising of prescription medicines.

The group argues that such ads are designed to persuade rather than inform, often using emotional appeals and visual tricks that highlight benefits while downplaying risks.

The request comes as the current administration has signaled a crackdown on what it deems deceptive drug advertising, announcing plans for stricter rules and enforcement last September.

Public Citizen hopes the FDA will act on the petition, adding to a wave of letters and public pressure aimed at tightening oversight of prescription drug promotion.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads”

read at STAT ↗
519 words · retrieved Jul 23
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY3LEADING2NOVO2ELI LILLY COGILEADNovo Nordisk Inc
drugs
Obesity
topics
GLP-1 receptorObesity

related stories

  • Oct 6The top biopharma conferences in 2027BioPharma Dive
  • Oct 2Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSBioSpace
  • Sep 30Lilly builds commercial case for GLP-1 products over Novo with indirect analysesBioSpace
  • Sep 29Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand HengruiFierce Biotech
  • Sep 28STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’STAT